Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity

Urothelial carcinoma of the bladder comprises two long-recognized disease entities with distinct molecular features and clinical outcome. Low-grade non-muscle-invasive tumours recur frequently but rarely progress to muscle invasion, whereas muscle-invasive tumours are usually diagnosed de novo and frequently metastasize. Recent genome-wide expression and sequencing studies identify genes and pathways that are key drivers of urothelial cancer and reveal a more complex picture with multiple molecular subclasses that traverse conventional grade and stage groupings. This improved understanding of molecular features, disease pathogenesis and heterogeneity provides new opportunities for prognostic application, disease monitoring and personalized therapy

Mitochondrial Mutations in Cancer Progression: Causative, Bystanders, or Modifiers of Tumorigenesis?

Mitochondrial DNA encodes genes that are de facto metabolic enzymes and are currently emerging as pivotal players in the origin, progression, and outcome of human cancers. We here revise the multifaceted implications of mitochondrial mutations on the metabolic reprogramming cancer cells must undergo to adapt and proliferate. The sources of such mutations and the processes that govern their positive selection are described, along with the consequences that a deranged respiratory metabolism may have on the remodeling that follows oncogenes activation or tumor suppressors ablation. Ultimately, we dwell on the peculiar features of oncocytic tumors, one of the most relevant yet mysterious models to functionally investigate the role of mitochondrial mutations in cancer